Scientist Fiona McDonnell, PhD, is using a first-of-its-kind technology to advance glaucoma research at the John A. Moran Eye Center. According to a November 13 report, McDonnell is using the iPerfusion 3 system to measure how fluid moves through healthy and diseased human eye tissue in real time.
McDonnell, an Ireland native who joined the Moran Eye Center in 2022, is a researcher at the Alan S. Crandall Center for Glaucoma Innovation. In 2025, she became the first researcher to use the iPerfusion 3 system, a custom-designed, next-generation technology.
In a healthy eye, a thin, clear fluid nourishes the cornea and lens. This fluid is constantly produced and removed; however, in many glaucoma patients, the fluid does not drain properly. This failure causes fluid buildup and increased pressure, which can damage the optic nerve responsible for carrying visual information to the brain.
The iPerfusion 3 system uses controlled-pressure systems and sensors to pump fluid through the natural drainage pathway of eyes gifted by organ donors. This allows McDonnell to adjust pressure and resistance to observe how the drainage system functions in real time.
McDonnell can also use the device to introduce medication to observe improvements in drainage. Additionally, she can test surgical devices designed to lower eye pressure by measuring how they change fluid flow and evaluating the eye for changes after placement.
McDonnell's work with this technology began after she discussed perfusion innovation with bioengineer Joseph van Batenburg-Sherwood, PhD. She provided research insights to help develop the custom-built machine and software.
This research is supported by funding from The Dick and Timmy Burton Foundation and a partnership with the Utah Lions Eye Bank, which recovers and distributes human eye tissue for research and vision restoration. A second iPerfusion 3 unit now serves as a shared research resource at the Moran Eye Center.
McDonnell noted that human donor tissue provides information that outweighs other sources, helping to answer critical questions relevant to helping patients. The technology addresses a major biomedical challenge by allowing researchers to test how the eye functions accurately without harming patients.